Alteogen Inc.
www.alteogen.com
Latest From Alteogen Inc.
Asia Deal Watch: Daiichi Sankyo Pays $200m To Ultragenyx For AAV Technology Access
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
Mylan's Aflibercept Biosimilar Gets Green Light For Trials In India
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.
Company Information
- Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
- Therapeutic Areas
- Cancer
- Immune Disorders
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
South Korea
-
South Korea
-
Pacific Rim
-
Asia
- Parent & Subsidiaries
- Alteogen Inc.
- Senior Management
-
Soon Jae Park, PhD, CEO
Moon Hwan Park, SVP, CFO
Hye-Shin Chung, PhD, CTO
Kyeong-Hoon Jeong, PhD, VP, Head R&D - Contact Info
-
Alteogen Inc.
Phone: 423848780
62 Yuseong-daero 1628, beon-gi
Yuseong-gu
Daejeon, 34054
South Korea